|
|
|
|
pmid:
|
Cuadros R et al. |
The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. |
2000 |
Cancer Lett. |
pmid:10754202
|
Yun JM et al. |
Efficient synthesis of enantiomerically pure 2-acylaziridines: Facile syntheses of N-Boc-safingol, N-Boc-D-erythro-sphinganine, and N-Boc-spisulosine from a common intermediate. |
2003 |
J. Org. Chem. |
pmid:14510541
|
Stokvis E et al. |
Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry. |
2003 |
J Mass Spectrom |
pmid:12794877
|
Maraschiello C et al. |
Phenylisothiocyanate and dansyl chloride precolumn derivatizations for the high-performance liquid chromatography analysis of the antitumoral agent ES-285 in dog plasma. |
2003 |
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. |
pmid:12798159
|
den Brok MW et al. |
Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285 x HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form. |
2003 |
J Chromatogr A |
pmid:14661748
|
Stokvis E et al. |
A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285. |
2004 |
Biomed. Chromatogr. |
pmid:15273982
|
Den Brok MW et al. |
Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl. |
2005 Jul-Aug |
PDA J Pharm Sci Technol |
pmid:16218203
|
Den Brok MW et al. |
Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices. |
2006 |
Pharmazie |
pmid:16454201
|
Faircloth G and Cuevas C |
Kahalalide F and ES285: potent anticancer agents from marine molluscs. |
2006 |
Prog. Mol. Subcell. Biol. |
pmid:17153351
|